Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649593 | 1.00 | KMT2A (0.48) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL29397325 | 1.00 | KMT2A (0.48) | KMT2AFABP5FABP7CASP3EPHX2 | |
| Water SCHEMBL21056515 | 0.99 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL29861643 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL30905364 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL29299774 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL31317449 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL31584391 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL31317420 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL25821923 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260007758-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| EP-4608452-A2 | PEPTIDE-ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Eisai R&D Management Co., Ltd. (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | Bicyclerd Limited (GB) | 2025-08-14 | — | — | US | disclosed |
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | BICYCLETX LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| WO-2024235136-A9 | HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| WO-2024235134-A9 | CONJUGATE HAVING TARGETING EFFECT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| US-12318454-B2 | Bicyclic peptide ligands specific for MT1-MMP | Bicyclerd Limited (GB) | 2025-06-03 | — | — | US | disclosed |
| EP-4559896-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE | National University Corporation Hokkaido University (JP) | 2025-05-28 | — | — | EP | disclosed |
| US-6352977-B1 | ALANINE WITH PRODRUGS | AVENTIS PHARMA LIMITED (GB) | 2002-03-05 | — | — | US | disclosed |
| EP-1042279-A1 | SUBSTITUTED BETA-ALANINES | Aventis Pharma Limited (GB) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033789-A1 | SUBSTITUTED β-ALANINES | AVENTIS PHARMA LIMITED (GB) | 1999-07-08 | — | — | WO | disclosed |
| US-5883237-A | PHOSPHODIESTER, PHOSPHOROTHIOATE, AND PHOSPHORODITHIOATE LINKAGES; O-(1,3,2-DICHALCOGEN-SUBSTITUTED-PHOSPHOLANE) SYNTHONS; ANTISENSE AGENTS | POLISH ACADEMY OF SCIENCE (PL) | 1999-03-16 | — | — | US | disclosed |
| EP-0506242-B1 | Method and compounds for solid phase synthesis of oligonucleotides and oligonucleotide analogs | POLISH ACADEMY OF SCIENCES CEN (PL) | 1998-12-09 | — | — | EP | disclosed |
| US-5646267-A | Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues | POLISH ACADEMY OF SCIENCES (PL) | 1997-07-08 | — | — | US | disclosed |
| WO-1995006751-A9 | METHODS FOR ISOLATION OF MOST ABUNDANT OLIGONUCLEOTIDES FROM COMPLEX MIXTURES | — | 1995-04-20 | — | — | WO | disclosed |
| WO-1995006751-A1 | METHODS FOR ISOLATION OF MOST ABUNDANT OLIGONUCLEOTIDES FROM COMPLEX MIXTURES | PHARMAGENICS, INC. (US) | 1995-03-09 | — | — | WO | disclosed |
| US-5359052-A | Solid phase synthesis of p-chiral oligonucleotides | POLISH ACADEMY OF SCIENCES (PL) | 1994-10-25 | — | — | US | disclosed |
| EP-0506242-A1 | Method and compounds for solid phase synthesis of oligonucleotides and oligonucleotide analogs | POLISH ACADEMY OF SCIENCES, Center of Molecular and Macromolecular Studies (PL) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | MMP11, MMP3, ANPEP | KMT2A 1306/4885FABP5 1749/4885FABP7 747/4885 |
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | KMT2A 1275/4885FABP5 2173/4885FABP7 3252/4885 |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | MMEL1, MMP3, TIMP3 | KMT2A 2286/4885FABP5 1547/4885FABP7 1488/4885 |
| US-12318454-B2 | Bicyclic peptide ligands specific for MT1-MMP | MMEL1, MMP3, TIMP3 | KMT2A 2286/4885FABP5 1547/4885FABP7 1488/4885 |
| US-20260007758-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOF | SSTR4, SSTR1, SSTR3 | KMT2A 3190/4885FABP5 2035/4885FABP7 1259/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | KMT2A 4608/4885FABP5 2565/4885FABP7 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.